Affinity Asset Advisors’s Centessa Pharmaceuticals CNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,400,000
| Closed | -$55.6M | – | 119 |
|
|
2026
Q1 | $55.6M | Buy |
1,400,000
+799,448
| +133% | +$20.4M | 2.87% | 8 |
|
|
2025
Q4 | $15M | Sell |
600,552
-506,610
| -46% | -$12.8M | 0.86% | 36 |
|
|
2025
Q3 | $26.8M | Buy |
1,107,162
+207,000
| +23% | +$3.68M | 2.34% | 15 |
|
|
2025
Q2 | $11.8M | Sell |
900,162
-646,500
| -42% | -$8.19M | 1.62% | 20 |
|
|
2025
Q1 | $22.2M | Buy |
1,546,662
+450,738
| +41% | +$7.38M | 2.12% | 11 |
|
|
2024
Q4 | $18.4M | Buy |
1,095,924
+130,312
| +13% | +$2.16M | 2.46% | 13 |
|
|
2024
Q3 | $15.4M | Sell |
965,612
-170,090
| -15% | -$2.08M | 2.11% | 15 |
|
|
2024
Q2 | $10.3M | Buy |
1,135,702
+305,156
| +37% | +$2.89M | 1.18% | 23 |
|
|
2024
Q1 | $9.39M | Buy |
830,546
+34,817
| +4% | +$330K | 1.16% | 26 |
|
|
2023
Q4 | $6.33M | Sell |
795,729
-222,362
| -22% | -$1.49M | 1.16% | 25 |
|
|
2023
Q3 | $6.59M | Buy |
1,018,091
+117,368
| +13% | +$803K | 1.85% | 19 |
|
|
2023
Q2 | $5.58M | Buy |
900,723
+216,596
| +32% | +$1.03M | 1.95% | 17 |
|
|
2023
Q1 | $2.63M | Buy |
684,127
+223,799
| +49% | +$819K | 0.87% | 32 |
|
|
2022
Q4 | $1.43M | Buy |
460,328
+217,811
| +90% | +$807K | 0.56% | 46 |
|
|
2022
Q3 | $975K | Buy |
+242,517
| New | +$1.11M | 0.27% | 52 |
|
|
2022
Q2 | – | Sell |
-65,282
| Closed | -$586K | – | 58 |
|
|
2022
Q1 | $586K | Sell |
65,282
-353,862
| -84% | -$3.23M | 0.09% | 53 |
|
|
2021
Q4 | $4.72M | Buy |
419,144
+215,961
| +106% | +$2.91M | 1.71% | 25 |
|
|
2021
Q3 | $3.39M | Buy |
203,183
+136,226
| +203% | +$2.82M | 0.86% | 29 |
|
|
2021
Q2 | $1.49M | Buy |
+66,957
| New | +$1.57M | 0.53% | 43 |
|
Affinity Asset Advisors's CNTA Position: Q2 2026 in Review
Affinity Asset Advisors sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 1,400,000 shares — an estimated $55.6M sold.
Affinity Asset Advisors first reported a position in CNTA in Q2 2021 and held it in 19 quarters. The position peaked at $55.6M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.
- Affinity Asset Advisors reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Affinity Asset Advisors sold 1,400,000 Centessa Pharmaceuticals shares in Q2 2026, an estimated $55.6M.
- Affinity Asset Advisors first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 19 quarters.
- Affinity Asset Advisors's Centessa Pharmaceuticals position peaked at $55.6M in Q1 2026.
- 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.
Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.